Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease
about
sameAs
The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factorLate stent thrombosis (> 1 year) following clopidogrel withdrawal after brachytherapy treatment: need to assess aspirin resistance?Aspirin resistance: an evaluation of current evidence and measurement methodsA critical appraisal of the phenomenon of aspirin resistanceAspirin resistanceAspirin resistance in secondary stroke preventionBiological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteersThromboelastography: potential bedside tool to assess the effects of antiplatelet therapy?Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) designAntithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actionsAspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphismThe PFA-100 detects sub-optimal antiplatelet responses in patients on aspirinAcetylsalicylic acid resistance and clinical outcome--the Hobikoglu study is worth notingPlatelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patientsAspirin resistance: Fact or fiction? A point of view.Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations.Variability and persistence of aspirin response in lower extremity peripheral arterial disease patientsAspirin prophylaxis for the prevention of thrombosis: expectations and limitationsAldose reductase, oxidative stress, and diabetic mellitus.Antiplatelet drug resistance: not ready for prime time.High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial)Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function.Thromboelastography for monitoring platelet function in unruptured intracranial aneurysm patients undergoing stent placement.The combination of EPA+DHA and low-dose aspirin ingestion reduces platelet function acutely whereas each alone may not in healthy humans.Thrombelastography: current clinical applications and its potential role in interventional cardiology.Aspirin and clopidogrel response variability: review of the published literaturePharmacogenomics of platelet responsiveness to aspirin.Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis.Aspirin resistance: biological and clinical implications.Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents.Aspirin resistance: A fact or a myth?Aspirin Resistance Predicts Adverse Cardiovascular Events in Patients with Symptomatic Peripheral Artery DiseaseAspirin resistance in patients with type II diabetes mellitus.Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence.Current status of antiplatelet agents to prevent stroke.Dosing strategies for antiplatelet therapy in percutaneous coronary intervention.Antiplatelet drug therapy: role of pharmacodynamic and genetic testing.Antiplatelet therapy: aspirin resistance and all that jazz!Advances in the monitoring of anti-P2Y12 therapy.
P2860
Q24794673-900056D8-754B-4E63-8D94-665D4C911454Q28166489-6FAC6454-BAE8-4D42-A191-9CC0A7C9C7AAQ28168370-E167A930-1621-4E57-A01F-5F04F667FFFDQ28183220-8B969D51-8E77-4BE7-BF79-078C8DE575A7Q28183919-6A6C2F8F-3595-4016-8381-44E93B2A5F19Q28187611-D017A07F-CDD2-4F90-B966-283FC919D949Q28194036-A79EBA4E-12FB-4300-9D16-BF645AD7E3F5Q28196714-C7AE2B3C-72EF-4C1B-8952-19012FDB60B6Q28200486-5C87731C-2745-4733-9539-3445D16B2E44Q28211902-10551DAD-2F82-4763-850E-DA8E5B980624Q28211940-0F7CF5B8-732F-4FF1-9B68-7D4420ACCCF0Q28217995-D8D1106A-251A-4E5F-AA53-8CAFA186F30CQ28218417-83AC5B0C-0E39-45F5-9BF1-48D5E6465071Q28220410-F8499316-76A8-4B78-BA4D-B738C01FBC45Q28220600-EC2B6C35-B5F3-41A5-87CB-7D45E5697207Q34389630-D755A41D-C461-4006-AAF4-49ECC53481E1Q35373683-432CDFB5-CFFF-4F2B-869A-B06C3CA7DEF8Q35400988-55E2C2F9-4D24-49C2-B21C-3EF00B184EC5Q35788838-FE953677-1152-4DF2-8FAF-FDF440A2D6E0Q35947855-2652C68C-C56A-4C05-9B2C-BD201845B445Q36289432-638ED712-7C08-424E-B2A2-57BC6654141CQ36366209-8427D408-403D-46A6-9DF3-31FD895E7E44Q36371688-16F8E705-DABD-4405-889C-DFB70693E6CCQ36589808-ED318B0C-C0BE-47E7-A029-80E76EE192CBQ36659192-D40CD709-4040-4CBF-8866-256719C1F588Q36664802-DA1456B1-D04C-48CF-BA2A-C6BF71D0A301Q36932221-D99060D6-B865-41A6-BFCC-DD99240E7B07Q36989841-9DEF5EDA-C04C-42DE-8BCC-678A1237AD9DQ37056745-4F698F8E-6981-4FA5-8881-345DB1EACF7BQ37089560-197806C4-2581-43C9-BC4F-4E3998CE6906Q37184596-4E2D43C0-C926-480B-BF4B-AB1C3C330F36Q37276469-9D680466-9F1D-4672-9B5A-AE27B5C897E8Q37527747-F69C5ED8-5068-4AEE-8064-A09914081938Q37564161-9272E954-166C-4EAB-A902-548516E67753Q37608580-C5626D87-B7E7-470D-B47D-1A53722BEA22Q37674733-E146924A-E350-4494-8887-5CF7D549E4D7Q37752222-5230872B-5036-44E4-A98E-F1FDC3CD5D06Q37882712-84545399-3881-4529-B611-5A118F8B898DQ38023196-591F9143-EF20-4156-902A-331C6A3FD029Q38037121-6B60A9F6-1862-49D9-BFEF-8D28C0FDD03A
P2860
Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Aspirin non-responsiveness as ...... s with coronary artery disease
@ast
Aspirin non-responsiveness as ...... s with coronary artery disease
@en
Aspirin non-responsiveness as ...... s with coronary artery disease
@nl
type
label
Aspirin non-responsiveness as ...... s with coronary artery disease
@ast
Aspirin non-responsiveness as ...... s with coronary artery disease
@en
Aspirin non-responsiveness as ...... s with coronary artery disease
@nl
prefLabel
Aspirin non-responsiveness as ...... s with coronary artery disease
@ast
Aspirin non-responsiveness as ...... s with coronary artery disease
@en
Aspirin non-responsiveness as ...... s with coronary artery disease
@nl
P2093
P1433
P1476
Aspirin non-responsiveness as ...... s with coronary artery disease
@en
P2093
Harald Arnesen
Ingebjørg Seljeflot
Kjell Andersen
Mette Hurlen
P356
10.1016/S0049-3848(02)00405-X
P407
P577
2002-10-01T00:00:00Z